UNSPSC 51283203: Josamycin

This classification denotes a macrolide antibiotic with the molecular formula C42H69NO15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HV13HFS217, chemically known as stereoisomer of 7-(formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-beta-d-glucopyranoside 4-acetate 4-isovalerate but generally known as josamycin, which bears US NIH Compound Identifier 5282165.

UNSPSC 51283203 Josamycin, a Commodity code, reflects state and local procurement of pharmaceutical products, though recent activity under this specific code shows limited relevant opportunities. The source records show one completed pharmaceutical warehouse award through the Illinois Department of Public Health via the MMCAP Infuse cooperative purchasing vehicle—a $2,999,999.11 contract with Chartwell Rx LLC for supply of Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets over 12 months with renewal options through year 3. The second record, a Seminole County, Florida procurement for Naloxone and Safe Drug Deactivation Systems, diverges substantially from the Josamycin code scope and appears to be a tagging mismatch rather than a representative example of the commodity itself.

Illinois Department of Public Health has demonstrated recent activity in pharmaceutical warehouse procurement through consortium vehicles. The geographic spread of recent activity is limited; the Illinois award represents the only clearly relevant state-level pharmaceutical solicitation in the source records. The Illinois contract utilized an Invitation for Bid (IFB) process and was completed in August 2026. State and local governments pursuing pharmaceutical supply contracts typically leverage cooperative purchasing agreements such as MMCAP Infuse to access pre-negotiated pricing and streamlined award processes, though the code itself shows sparse recent opportunity flow compared to broader pharmaceutical categories.